Boothbay Fund Management’s Esperion Therapeutics ESPR Stock Holding History

Boothbay Fund Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-233,800	Closed	-$1.46M	–	2245
2022 Q4	$1.46M	Buy	233,800 +199,200	+576%	+$1.42M	0.03%	734
2022 Q3	$232K	Buy	+34,600	New	+$238K	0.01%	1710
2018 Q4	–	Sell	-402	Closed	-$1.78M	–	723
2018 Q3	$1.78M	Buy	+402	New	+$18.5K	0.18%	109
2018 Q1	–	Sell	-211	Closed	-$1.39M	–	734
2017 Q4	$1.39M	Buy	+211	New	+$11.4K	0.2%	97
2017 Q3	–	Sell	-30,700	Closed	-$1.42M	–	644
2017 Q2	$1.42M	Buy	+30,700	New	+$1.13M	0.3%	67

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Boothbay Fund Management's ESPR Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 30,000 shares worth $94.8K. The stake represents ﹤0.01% of the portfolio and ranks #2058 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in ESPR as recently as Q3 2024.

Boothbay Fund Management first reported a position in ESPR in Q2 2022 and has held it in 11 quarters since. The position peaked at $1.76M in Q3 2022. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Boothbay Fund Management held 30,000 shares of Esperion Therapeutics worth $94.8K as of Q2 2026.
Esperion Therapeutics was a new Boothbay Fund Management position in Q2 2026.
Esperion Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2058 holding.
Boothbay Fund Management first reported a position in Esperion Therapeutics in Q2 2022 and has held it in 11 quarters since.
Boothbay Fund Management's Esperion Therapeutics position peaked at $1.76M in Q3 2022.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.